Formalin-fixed, paraffin-embedded human Hepatocellular Carcinoma stained with Glypican-3 Mouse Recombinant Monoclonal Ab (rGPC3/863).
SDS-PAGE Analysis Purified Glypican-3 Mouse Recombinant Monoclonal Ab (rGPC3/863). Confirmation of Integrity and Purity of Antibody.
Immunofluorescence Analysis of MeOH-fixed HepG2 cells labeling Glypican-3 with Glypican-3 Mouse Recombinant Monoclonal Ab (rGPC3/863) followed by Goat anti-Mouse IgG-CF488 (Green). The nuclear counterstain is Reddot (Red).
Flow Cytometric Analysis of MeOH-fixed HepG2 cells using Glypican-3 Mouse Recombinant Monoclonal Ab (rGPC3/863) followed by Goat anti- Mouse- IgG-CF488 (Blue); Isotype Control (Red).
Analysis of Protein Array containing more than 19,000 full-length human proteins using Mouse Glypican-3 Recombinant Monoclonal Antibody (rGPC3/863)
Known Applications & Suggested Dilutions
Host / Ig Isotype
Mol. Weight of Antigen
Specificity & Comments
Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm's tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm's tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.